FDG PET/CT in Pancreatic and Hepatobiliary Carcinomas: Value to Patient Management and Patient Outcomes.
Publication
, Journal Article
Parikh, U; Marcus, C; Sarangi, R; Taghipour, M; Subramaniam, RM
Published in: PET Clin
July 2015
Fludeoxyglucose F 18 ((18)F-FDG) PET/CT has not been shown to offer additional benefit in the initial diagnosis of pancreatic cancer, but studies show benefit of (18)F-FDG PET/CT in initial staging and patient prognosis. There is evidence for (18)F-FDG PET and (18)F-FDG PET/CT in staging and prognosis of cholangiocarcinoma and gallbladder cancer. (18)F-FDG PET/CT has shown promise in staging liver malignancies by detecting extrahepatic metastasis. There is evidence supporting the ability of PET/CT in predicting prognosis in patients with hepatocellular carcinoma. Evidence is evolving for the role of (18)F-FDGPET/CT in predicting prognosis and survival in patients with colorectal liver metastasis.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
PET Clin
DOI
EISSN
1879-9809
Publication Date
July 2015
Volume
10
Issue
3
Start / End Page
327 / 343
Location
United States
Related Subject Headings
- Treatment Outcome
- Tomography, X-Ray Computed
- Radiopharmaceuticals
- Prognosis
- Positron-Emission Tomography
- Pancreatic Neoplasms
- Nuclear Medicine & Medical Imaging
- Neoplasm Staging
- Multimodal Imaging
- Male
Citation
APA
Chicago
ICMJE
MLA
NLM
Parikh, U., Marcus, C., Sarangi, R., Taghipour, M., & Subramaniam, R. M. (2015). FDG PET/CT in Pancreatic and Hepatobiliary Carcinomas: Value to Patient Management and Patient Outcomes. PET Clin, 10(3), 327–343. https://doi.org/10.1016/j.cpet.2015.03.001
Parikh, Ujas, Charles Marcus, Rutuparna Sarangi, Mehdi Taghipour, and Rathan M. Subramaniam. “FDG PET/CT in Pancreatic and Hepatobiliary Carcinomas: Value to Patient Management and Patient Outcomes.” PET Clin 10, no. 3 (July 2015): 327–43. https://doi.org/10.1016/j.cpet.2015.03.001.
Parikh U, Marcus C, Sarangi R, Taghipour M, Subramaniam RM. FDG PET/CT in Pancreatic and Hepatobiliary Carcinomas: Value to Patient Management and Patient Outcomes. PET Clin. 2015 Jul;10(3):327–43.
Parikh, Ujas, et al. “FDG PET/CT in Pancreatic and Hepatobiliary Carcinomas: Value to Patient Management and Patient Outcomes.” PET Clin, vol. 10, no. 3, July 2015, pp. 327–43. Pubmed, doi:10.1016/j.cpet.2015.03.001.
Parikh U, Marcus C, Sarangi R, Taghipour M, Subramaniam RM. FDG PET/CT in Pancreatic and Hepatobiliary Carcinomas: Value to Patient Management and Patient Outcomes. PET Clin. 2015 Jul;10(3):327–343.
Published In
PET Clin
DOI
EISSN
1879-9809
Publication Date
July 2015
Volume
10
Issue
3
Start / End Page
327 / 343
Location
United States
Related Subject Headings
- Treatment Outcome
- Tomography, X-Ray Computed
- Radiopharmaceuticals
- Prognosis
- Positron-Emission Tomography
- Pancreatic Neoplasms
- Nuclear Medicine & Medical Imaging
- Neoplasm Staging
- Multimodal Imaging
- Male